health
Bioavailability Improvement
Bioavailability Improvement refers to an effect associated with making a substance more available for the body to absorb or use. In this library, it is treated as a health-related effect rather than a standalone ingredient, and it appears across multiple interventions.
Bioavailability improvement refers to how an ingredient may help another be absorbed or used more effectively. This page explains the concept in simple terms.
These are research findings, not promises. Most options have little evidence, and results differ from person to person.
What may help
None of these options has good evidence yet. Best evidence first.
1 option:1 personal stories only
Wim Hof Method BreathingpracticeOnly personal stories
Only people's own stories online. No study has tested it.
Based on one study.
Open the Wim Hof Method Breathing page
The expert view shows every study, dose protocol and source.
What may help
Linked to improving it1 listedStart here
The best we have, but the evidence is still weak
How to read the evidence
Evidence tier — overall strength of the evidence for the whole compound
- StrongWell established — backed by strong, consistent human research.
- ModerateSome genuine support, but mostly from small or lower-quality studies. Promising, not proven.
- PreliminaryEarly-stage evidence — a promising hypothesis, not an established effect yet.
- LimitedVery limited evidence — treat this as a hypothesis, not proof.
- InsufficientNot enough good evidence to draw conclusions yet.
Certainty — how sure we can be that the effect is real
- Very highVery sure — strong, consistent evidence
- HighFairly sure — consistent evidence from good studies
- MediumModerately sure — new studies could change this
- LowNot sure — little or mixed evidence
- Very lowVery unsure — almost no usable evidence
Source — where the data comes from
- Meta-analysisPooled analysis of many trials — the strongest evidence
- RCTRandomized controlled trial — a strong human study design
- ClinicalA human clinical study
- Reference knowledgeFrom general health-science or pharmacology references, not a study of this exact claim
- Animal researchStudied in animals, not humans
- Community reportsAggregated user reports — anecdotal signal, not evidence
- TheoreticalMechanism-based reasoning, not yet tested
Study grade — quality of each underlying study (A best, D weakest)
- AHigh-quality — strong, consistent human trials
- BGood — solid evidence with some limitations
- CModerate — limited, small, or mixed-quality studies
- DWeak — preliminary, indirect, or animal-only
Confidence — how strongly the sources back a finding
A 0–100 score from study quality and agreement
Most supplement evidence is graded C–D. Read it as preliminary signal, not proof.
Full write-up
What is it
Bioavailability Improvement refers to an effect associated with making a substance more available for the body to absorb or use. In this library, it is treated as a health-related effect rather than a standalone ingredient, and it appears across multiple interventions.
The label does not by itself say how strong the effect is, which product causes it, or what outcome it leads to. It is mainly a way to group interventions that may influence how well something is taken up or utilized.
How interventions help
The available evidence suggests that these interventions may help improve bioavailability, meaning they could support how well another substance is absorbed or made available to the body. Most of the entries here are supported only by pharmacology references, and the overall confidence is low, so this is best read as a signal of possible interaction rather than a strong or established effect.
A few interventions stand out because they are listed with low probability, including Bromelain, Piperine (BioPerine), Betaine HCl, Boron, Cellulase, Citrulline, Fulvic Acid, Omega-9, Sulbutiamine, and Vitamin D. Resveratrol is also included with low probability, but its support is from a review rather than a pharmacology reference. Goldenseal, N-Acetyl-L-Tyrosine (NALT), and Quercetin are listed with very low probability, which suggests even less certainty.
In practical terms, this means the effect is plausible for some of these interventions, but the data does not support treating them as dependable bioavailability enhancers. The number of articles behind each entry is also small, so the evidence base is limited and uneven.
Choosing guidance
This effect is associated with several ingredients that may improve bioavailability, but the overall strength of evidence is limited. Most entries are supported by pharmacology reference data, and one is supported by a review, so this is best read as a preliminary signal rather than a strong conclusion.
If you are comparing options, the main point is that some ingredients appear more often in the evidence than others. Bromelain, Piperine (BioPerine), and a few others appear with low probability, while Goldenseal, N-Acetyl-L-Tyrosine (NALT), and Quercetin are listed with very low probability. That difference suggests a weaker signal for the latter group, not a complete absence of any relationship.
Because the evidence is sparse and uneven, it is more useful to think about this category as a general pattern than as a definitive recommendation. The article count attached to each ingredient also varies, which can help you gauge how much information is available. In practice, the selection question is less about identifying a clear winner and more about recognizing that the current support is limited across the board.